Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986158 · 2 trials · 2 indications
Number of participants experiencing different types of events, including Adverse Events (AEs), Serious Adverse Events (SAEs), AEs leading to discontinuation and deaths. Events are classified based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Number of participants experiencing abnormal hepatic function, as measured by different parameters. ALT = Alanine aminotransferase AST = Aspartate aminotransferase ULN = Upper Limit of Normal
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 1B: BMS-986158 + Fedratinib | EXPERIMENTAL | - |
| Part 2A1: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 2B1: BMS-986158 + Fedratinib | EXPERIMENTAL | - |
| Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable | EXPERIMENTAL | - |
| Part 2A2 Add-On: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Part 2A3: BMS-986158 + Ruxolitinib | EXPERIMENTAL | - |
| Monotherapy Treatment | EXPERIMENTAL | Patients treated at various doses and schedules |
| Combination Therapy | EXPERIMENTAL | Patients treated at selected doses and schdules |
| Name | Type | Description |
|---|---|---|
| BMS-986158 | DRUG | Specified dose on specified days |
| Ruxolitinib | DRUG | Specified dose on specified days |
| Fedratinib | DRUG | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
Inclusion Criteria: * Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis * Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment ...
Top 20 of 45 competitors
BMS-986158 is an investigational small molecule being studied for the treatment of myelofibrosis and advanced tumors. It is in Phase 1 clinical development by Bristol-Myers Squibb Company (BMY). The drug is not approved and remains under investigation in clinical trials.
BMS-986158 is a small molecule being developed by Bristol-Myers Squibb. Its specific molecular target has not been disclosed in available information. The drug is being studied in Phase 1 trials for myelofibrosis and advanced tumors.
BMS-986158 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with myelofibrosis and advanced tumors.
BMS-986158 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Bristol-Myers Squibb is studying it in patients with myelofibrosis and advanced tumors to assess safety, tolerability, and preliminary efficacy.
BMS-986158 is being studied in two Phase 1 trials. NCT02419417, completed, enrolled 83 participants with advanced tumors. NCT04817007, active but not recruiting, is assessing the drug alone and with ruxolitinib or fedratinib in 216 participants with myelofibrosis.
BMS-986158 is the primary name for this investigational compound. No alternative names have been identified in available information. It is a small molecule being developed by Bristol-Myers Squibb for oncology indications.